Repare Therapeutics Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 82.52. In total, the insiders bought 4 307 513 and sold 2 168 089 RPTX shares in the last 100 trades.

Insider Power

(Last 100 transactions)
82.52
Buy 4 307 513 Shares
Sell 2 168 089 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 17, 2024 Stock Option (right to buy) Buy Schafer Carol 27 200
Jun 17, 2024 Stock Option (right to buy) Buy Rhoads Ann D 27 200
Jun 17, 2024 Stock Option (right to buy) Buy Morrison Briggs 27 200
Jun 17, 2024 Stock Option (right to buy) Buy Molineaux Susan 27 200
Jun 17, 2024 Stock Option (right to buy) Buy Kulkarni Samarth 27 200
Jun 17, 2024 Stock Option (right to buy) Buy Bonita David P 27 200
Jun 17, 2024 Stock Option (right to buy) Buy Civik Thomas 27 200
Jun 17, 2024 Stock Option (right to buy) Buy Stein Steven H 54 000
Jun 17, 2024 Buy Stein Steven H 0
Apr 01, 2024 Common Shares Sell Segal Lloyd Mitchell 2 491
Apr 01, 2024 Common Shares Sell Forte Steve 789
Apr 01, 2024 Common Shares Sell Zinda Michael 410
Apr 01, 2024 Common Shares Sell Koehler Maria 300
Mar 28, 2024 Common Shares Sell Segal Lloyd Mitchell 2 650
Mar 28, 2024 Common Shares Sell Forte Steve 825
Mar 28, 2024 Common Shares Sell Zinda Michael 450
Mar 28, 2024 Common Shares Sell Koehler Maria 500
Mar 27, 2024 Common Shares Sell Forte Steve 825
Mar 27, 2024 Common Shares Sell Zinda Michael 450
Mar 27, 2024 Common Shares Sell Koehler Maria 500
Mar 27, 2024 Common Shares Sell Segal Lloyd Mitchell 2 650
Mar 26, 2024 Common Shares Sell Forte Steve 825
Mar 26, 2024 Common Shares Sell Zinda Michael 450
Mar 26, 2024 Common Shares Sell Koehler Maria 500
Mar 26, 2024 Common Shares Sell Segal Lloyd Mitchell 2 650
Click to get the best stock tips daily for free!

About Repare Therapeutics Inc.

Repare Therapeutics. Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an ora... RPTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT